BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 31119463)

  • 1. NOP-Targeted Nonpeptide Ligands.
    Zaveri NT; Meyer ME
    Handb Exp Pharmacol; 2019; 254():37-67. PubMed ID: 31119463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic.
    Thompson AA; Liu W; Chun E; Katritch V; Wu H; Vardy E; Huang XP; Trapella C; Guerrini R; Calo G; Roth BL; Cherezov V; Stevens RC
    Nature; 2012 May; 485(7398):395-9. PubMed ID: 22596163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological activity of small peptides as NOP and opioid receptors' ligands: view on current developments.
    Naydenova E; Todorov P; Zamfirova R
    Vitam Horm; 2015; 97():123-46. PubMed ID: 25677770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity.
    Guerrini R; Carra' G; Calo' G; Trapella C; Marzola E; Rizzi D; Regoli D; Salvadori S
    J Pept Res; 2004 Jun; 63(6):477-84. PubMed ID: 15175020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of Nociceptin/Orphanin FQ Peptide Analogs for Drug Development.
    Wtorek K; Janecka A
    Chem Biodivers; 2021 Jan; 18(1):e2000871. PubMed ID: 33351271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor.
    Calo G; Guerrini R; Rizzi A; Salvadori S; Burmeister M; Kapusta DR; Lambert DG; Regoli D
    CNS Drug Rev; 2005; 11(2):97-112. PubMed ID: 16007234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.
    Calo' G; Rizzi A; Cifani C; Micioni Di Bonaventura MV; Regoli D; Massi M; Salvadori S; Lambert DG; Guerrini R
    CNS Neurosci Ther; 2011 Jun; 17(3):178-98. PubMed ID: 20497197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of small-molecule nonpeptide antagonists of nociceptin/orphanin FQ receptor: The studies of design, synthesis, and structure-activity relationships for (4-arylpiperidine substituted-methyl)-[bicyclic (hetero)cycloalkanobenzene] derivatives.
    Hayashi S; Ohashi K; Mihara S; Nakata E; Emoto C; Ohta A
    Eur J Med Chem; 2016 May; 114():345-64. PubMed ID: 27043173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NOP-Targeted Peptide Ligands.
    Preti D; Caló G; Guerrini R
    Handb Exp Pharmacol; 2019; 254():17-36. PubMed ID: 30689091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential In Vitro Pharmacological Profiles of Structurally Diverse Nociceptin Receptor Agonists in Activating G Protein and Beta-Arrestin Signaling at the Human Nociceptin Opioid Receptor.
    Lu JJ; Polgar WE; Mann A; Dasgupta P; Schulz S; Zaveri NT
    Mol Pharmacol; 2021 Jul; 100(1):7-18. PubMed ID: 33958480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.
    Toll L; Bruchas MR; Calo' G; Cox BM; Zaveri NT
    Pharmacol Rev; 2016 Apr; 68(2):419-57. PubMed ID: 26956246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of NOP-Related Ligands in Nonhuman Primates.
    Kiguchi N; Ko MC
    Handb Exp Pharmacol; 2019; 254():323-343. PubMed ID: 30879202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NOP Receptor Signaling Cascades.
    Parker KE; Bruchas MR
    Handb Exp Pharmacol; 2019; 254():131-139. PubMed ID: 31087192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands.
    Viaro R; Calcagno M; Marti M; Borrelli E; Morari M
    Neuropharmacology; 2013 Sep; 72():126-38. PubMed ID: 23643745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recently patented and promising ORL-1 ligands: where have we been and where are we going?
    Largent-Milnes TM; Vanderah TW
    Expert Opin Ther Pat; 2010 Mar; 20(3):291-305. PubMed ID: 20180617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure- and conformation-activity studies of nociceptin/orphanin FQ receptor dimeric ligands.
    Pacifico S; Carotenuto A; Brancaccio D; Novellino E; Marzola E; Ferrari F; Cerlesi MC; Trapella C; Preti D; Salvadori S; Calò G; Guerrini R
    Sci Rep; 2017 Apr; 7():45817. PubMed ID: 28383520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nociceptin/orphanin FQ peptide receptor as a therapeutic target for obesity.
    Przydzial MJ; Heisler LK
    Mini Rev Med Chem; 2008 Jul; 8(8):796-811. PubMed ID: 18673136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120.
    Fischetti C; Rizzi A; Gavioli EC; Marzola G; Trapella C; Guerrini R; Petersen JS; Calo G
    Peptides; 2009 Feb; 30(2):248-55. PubMed ID: 18992780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics.
    Kiguchi N; Ding H; Kishioka S; Ko MC
    Curr Top Med Chem; 2020; 20(31):2878-2888. PubMed ID: 32384033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NOP-Related Mechanisms in Pain and Analgesia.
    Toll L; Ozawa A; Cippitelli A
    Handb Exp Pharmacol; 2019; 254():165-186. PubMed ID: 31119465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.